vs
Side-by-side financial comparison of Biogen (BIIB) and Ralph Lauren Corporation (RL). Click either name above to swap in a different company.
Ralph Lauren Corporation is the larger business by last-quarter revenue ($2.4B vs $2.3B, roughly 1.1× Biogen). Ralph Lauren Corporation runs the higher net margin — 15.0% vs -2.1%, a 17.2% gap on every dollar of revenue. On growth, Ralph Lauren Corporation posted the faster year-over-year revenue change (12.2% vs -7.1%). Ralph Lauren Corporation produced more free cash flow last quarter ($704.0M vs $468.0M). Over the past eight quarters, Ralph Lauren Corporation's revenue compounded faster (23.9% CAGR vs -0.2%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Ralph Lauren is an American fashion designer, philanthropist, and billionaire businessman, best known for founding the brand Ralph Lauren, a global multibillion-dollar enterprise. He stepped down as CEO of the company in September 2015 but remains executive chairman and chief creative officer. As of May 2025, his net worth is estimated at US$11.9 billion.
BIIB vs RL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $2.4B |
| Net Profit | $-48.9M | $361.6M |
| Gross Margin | 78.3% | 69.9% |
| Operating Margin | -2.5% | 19.6% |
| Net Margin | -2.1% | 15.0% |
| Revenue YoY | -7.1% | 12.2% |
| Net Profit YoY | -118.3% | 21.6% |
| EPS (diluted) | $-0.35 | $5.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $2.4B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $1.7B | ||
| Q1 25 | $2.4B | $1.7B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.5B | $1.7B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | $2.3B | $1.6B |
| Q4 25 | $-48.9M | $361.6M | ||
| Q3 25 | $466.5M | $207.5M | ||
| Q2 25 | $634.8M | $220.4M | ||
| Q1 25 | $240.5M | $129.0M | ||
| Q4 24 | $266.7M | $297.4M | ||
| Q3 24 | $388.5M | $147.9M | ||
| Q2 24 | $583.6M | $168.6M | ||
| Q1 24 | $393.4M | $90.7M |
| Q4 25 | 78.3% | 69.9% | ||
| Q3 25 | 73.4% | 68.0% | ||
| Q2 25 | 77.1% | 72.3% | ||
| Q1 25 | 74.1% | 68.7% | ||
| Q4 24 | 76.2% | 68.4% | ||
| Q3 24 | 74.1% | 67.0% | ||
| Q2 24 | 77.8% | 70.5% | ||
| Q1 24 | 76.3% | 66.6% |
| Q4 25 | -2.5% | 19.6% | ||
| Q3 25 | 22.0% | 12.2% | ||
| Q2 25 | 28.1% | 15.9% | ||
| Q1 25 | 12.8% | 9.1% | ||
| Q4 24 | 11.9% | 18.2% | ||
| Q3 24 | 18.3% | 10.4% | ||
| Q2 24 | 28.3% | 13.8% | ||
| Q1 24 | 20.3% | 6.9% |
| Q4 25 | -2.1% | 15.0% | ||
| Q3 25 | 18.4% | 10.3% | ||
| Q2 25 | 24.0% | 12.8% | ||
| Q1 25 | 9.9% | 7.6% | ||
| Q4 24 | 10.9% | 13.9% | ||
| Q3 24 | 15.8% | 8.6% | ||
| Q2 24 | 23.7% | 11.1% | ||
| Q1 24 | 17.2% | 5.8% |
| Q4 25 | $-0.35 | $5.82 | ||
| Q3 25 | $3.17 | $3.32 | ||
| Q2 25 | $4.33 | $3.52 | ||
| Q1 25 | $1.64 | $2.03 | ||
| Q4 24 | $1.82 | $4.66 | ||
| Q3 24 | $2.66 | $2.31 | ||
| Q2 24 | $4.00 | $2.61 | ||
| Q1 24 | $2.70 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.3B |
| Total DebtLower is stronger | $6.3B | — |
| Stockholders' EquityBook value | $18.3B | $2.9B |
| Total Assets | $29.4B | $7.8B |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
| Q4 25 | $18.3B | $2.9B | ||
| Q3 25 | $18.2B | $2.6B | ||
| Q2 25 | $17.6B | $2.5B | ||
| Q1 25 | $17.0B | $2.6B | ||
| Q4 24 | $16.7B | $2.5B | ||
| Q3 24 | $16.4B | $2.4B | ||
| Q2 24 | $15.9B | $2.4B | ||
| Q1 24 | $15.2B | $2.5B |
| Q4 25 | $29.4B | $7.8B | ||
| Q3 25 | $29.2B | $7.3B | ||
| Q2 25 | $28.3B | $7.8B | ||
| Q1 25 | $28.0B | $7.0B | ||
| Q4 24 | $28.0B | $7.1B | ||
| Q3 24 | $28.3B | $6.8B | ||
| Q2 24 | $26.8B | $6.6B | ||
| Q1 24 | $26.6B | $6.6B |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $779.6M |
| Free Cash FlowOCF − Capex | $468.0M | $704.0M |
| FCF MarginFCF / Revenue | 20.5% | 29.3% |
| Capex IntensityCapex / Revenue | 1.9% | 3.1% |
| Cash ConversionOCF / Net Profit | — | 2.16× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | $694.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $779.6M | ||
| Q3 25 | $1.3B | $53.2M | ||
| Q2 25 | $160.9M | $176.1M | ||
| Q1 25 | $259.3M | $122.2M | ||
| Q4 24 | $760.9M | $738.4M | ||
| Q3 24 | $935.6M | $97.2M | ||
| Q2 24 | $625.8M | $277.3M | ||
| Q1 24 | $553.2M | — |
| Q4 25 | $468.0M | $704.0M | ||
| Q3 25 | $1.2B | $-40.6M | ||
| Q2 25 | $134.3M | $-11.2M | ||
| Q1 25 | $222.2M | $42.3M | ||
| Q4 24 | $721.6M | $677.2M | ||
| Q3 24 | $900.6M | $55.5M | ||
| Q2 24 | $592.3M | $243.9M | ||
| Q1 24 | $507.3M | — |
| Q4 25 | 20.5% | 29.3% | ||
| Q3 25 | 48.4% | -2.0% | ||
| Q2 25 | 5.1% | -0.7% | ||
| Q1 25 | 9.1% | 2.5% | ||
| Q4 24 | 29.4% | 31.6% | ||
| Q3 24 | 36.5% | 3.2% | ||
| Q2 24 | 24.0% | 16.1% | ||
| Q1 24 | 22.1% | — |
| Q4 25 | 1.9% | 3.1% | ||
| Q3 25 | 1.8% | 4.7% | ||
| Q2 25 | 1.0% | 10.9% | ||
| Q1 25 | 1.5% | 4.7% | ||
| Q4 24 | 1.6% | 2.9% | ||
| Q3 24 | 1.4% | 2.4% | ||
| Q2 24 | 1.4% | 2.2% | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | 2.16× | ||
| Q3 25 | 2.73× | 0.26× | ||
| Q2 25 | 0.25× | 0.80× | ||
| Q1 25 | 1.08× | 0.95× | ||
| Q4 24 | 2.85× | 2.48× | ||
| Q3 24 | 2.41× | 0.66× | ||
| Q2 24 | 1.07× | 1.64× | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
RL
Segment breakdown not available.
